Ignite Creation Date:
2024-05-06 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05334849
Status:
COMPLETED
Last Update Posted:
2022-10-12
First Post:
2022-04-06
Brief Title:
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Sponsor:
Lin Chen
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
Prospectively Predict the Efficacy of Precise Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To vertify the function of circulating exosomal lncRNA-GC1 on predicting and monitoring immunotherapeutic outcomes of GC
Detailed Description:
The investigators previous work identified circulating exosomal lncRNA-GC1 as a GC-specific tumor burden marker and this novel biomarker showed promising efficiency in monitoring disease progression during treatment
Hence in this stuty the investigator plan to recruit a prospective cohort to support the conclusions and provide biomarkers to realize predicting and monitoring immunotherapeutic outcomes of GC
Hence in this stuty the investigator plan to recruit a prospective cohort to support the conclusions and provide biomarkers to realize predicting and monitoring immunotherapeutic outcomes of GC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None